Skip to main content
Premium Trial:

Request an Annual Quote

PositiveID Collaborates With US Military to Further Develop Handheld Real-time PCR Device

NEW YORK (GenomeWeb) – PositiveID today announced an agreement with the US Special Operations Command Research, Development, and Acquisition Center to further develop military applications for the company's real-time PCR pathogen detection system, Firefly Dx.

Firefly Dx is a handheld system that can deliver molecular diagnostic results at the point of need using Thermo Fisher Scientific Life Technologies' TaqMan PCR chemistry. It can derive results from a sample in less than 20 minutes, as opposed to two to four hours for a laboratory-based device, the company said in a statement.

Under the agreement, PositiveID will receive requirements, priorities, feedback, and human factors/human systems integration support from USSOCOM as it develops Firefly Dx for applications in Special Operations Forces missions. Financial and other terms of the agreement were not disclosed.

Earlier this year, the Delray Beach, Fla.-based firm signed an agreement with NASA to test Firefly Dx for use in space. The firm eventually plans to move into clinical testing.

PositiveID is focused on developing microfluidic systems for the automated detection and analysis of biological threats and other samples.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more